Carnitine in metabolic disease: Potential for pharmacological intervention

被引：70
作者：
Arduini, Arduino [1 ]
Bonomini, Mario [2 ]
Savica, Vincenzo [3 ]
Amato, Antonino [4 ]
Zammit, Victor
机构：
[1] Iperboreal Pharma Srl, R&D Dept, Chieti, Italy
[2] Univ Hosp Chieti, Dept Nephrol & Dialysis, Chieti, Italy
[3] Univ Messina, Nephrol & Dialysis Unit, Messina, Italy
[4] Sigma Tau Pharmaceut Spa, Clin Res Unit, Pomezia, Italy
来源：
PHARMACOLOGY & THERAPEUTICS | 2008年 / 120卷 / 02期
关键词：
L-carnitine; Hemodialysis; Uremia; Peritoneal dialysis; Insulin resistance; Diabetes; Metabolism; Dyslipidemia;
D O I：
10.1016/j.pharmthera.2008.08.008
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
L-carnitine (LC) deficiency is commonly observed in chronic hemodialysis (HD) patients. As a result of this and other causes of secondary LC deficiencies, LC has been described as a "conditionally essential nutrient" or "conditional vitamin". Although a large number of clinical trials regarding the beneficial effects of LC administration in HD patients have been published, some controversy about its use in this indication persists. In this article, we will review the use of LC in dialysis patients, by focussing mainly on those experimental and clinical data supporting the notion that supra-physiological concentrations of LC in plasma and target organs may exert beneficial effects on several metabolic parameters that have derangements of a common origin (e.g. insulin resistance, type 2 diabetes, dyslipidemia) and which are frequently present in end-stage renal disease (ESRD) patients undergoing dialysis. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码：149 / 156
页数：8
相关论文
共 82 条
[41]   Effects of oral L-carnitine supplementation on in vivo long-chain fatty acid oxidation in healthy adults [J].
Müller, DM ;
Seim, H ;
Kiess, W ;
Löster, H ;
Richter, T .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2002, 51 (11) :1389-1391
[42]  
ONTKO JA, 1990, J LIPID RES, V31, P1983
[43]   Opinion - How many drug targets are there? [J].
Overington, John P. ;
Al-Lazikani, Bissan ;
Hopkins, Andrew L. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (12) :993-996
[44]   Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes [J].
Petersen, KF ;
Dufour, S ;
Befroy, D ;
Lehrke, M ;
Hendler, RE ;
Shulman, GI .
DIABETES, 2005, 54 (03) :603-608
[45]   Carnitine revisited: potential use as adjunctive treatment in diabetes [J].
Power, R. A. ;
Hulver, M. W. ;
Zhang, J. Y. ;
Dubois, J. ;
Marchand, R. M. ;
Ilkayeva, O. ;
Muoio, D. M. ;
Mynatt, R. L. .
DIABETOLOGIA, 2007, 50 (04) :824-832
[46]   Impact of dyslipidemia in end-stage renal disease [J].
Prichard, SS .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (09) :S315-S320
[47]   Fructose-induced hepatic gluconeogenesis: Effect of L-carnitine [J].
Rajasekar, Panchamoorthy ;
Anuradha, Carani Venkatraman .
LIFE SCIENCES, 2007, 80 (13) :1176-1183
[48]  
Ramsay Rona R., 2004, Molecular Aspects of Medicine, V25, P475, DOI 10.1016/j.mam.2004.06.002
[49]   A snapshot of carnitine acetyltransferase [J].
Ramsay, RR ;
Naismith, JH .
TRENDS IN BIOCHEMICAL SCIENCES, 2003, 28 (07) :343-346
[50]   THE CARNITINE ACYLTRANSFERASES AND THEIR ROLE IN MODULATING ACYL-COA POOLS [J].
RAMSAY, RR ;
ARDUINI, A .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1993, 302 (02) :307-314
123456789